Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

BACKGROUND: Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Several retrospective analysis suggested clinical cross-resistance between these agents in patients previously treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yoko, Matsubara, Nobuaki, Tabata, Ken-ichi, Satoh, Takefumi, Kamiya, Naoto, Suzuki, Hiroyoshi, Kawahara, Takashi, Uemura, Hiroji, Yano, Akihiro, Kawakami, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069876/
https://www.ncbi.nlm.nih.gov/pubmed/27756383
http://dx.doi.org/10.1186/s13104-016-2279-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069876/
https://www.ncbi.nlm.nih.gov/pubmed/27756383
http://dx.doi.org/10.1186/s13104-016-2279-9

Ejemplares similares